Sotera Health (NYSE:SHC) Issues FY 2021 Earnings Guidance

Sotera Health (NYSE:SHC) issued an update on its FY 2021 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.870-$0.880 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.890. The company issued revenue guidance of $920 million-$930 million, compared to the consensus revenue estimate of $932.86 million.

Shares of SHC traded up $0.10 during mid-day trading on Thursday, reaching $21.91. 657,454 shares of the company’s stock were exchanged, compared to its average volume of 987,015. The company has a quick ratio of 2.46, a current ratio of 2.52 and a debt-to-equity ratio of 3.39. The company has a 50-day simple moving average of $25.20 and a two-hundred day simple moving average of $24.38. Sotera Health has a 52-week low of $21.18 and a 52-week high of $30.38. The company has a market cap of $6.20 billion and a price-to-earnings ratio of 182.60.

Sotera Health (NYSE:SHC) last issued its quarterly earnings data on Wednesday, November 10th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.02. Sotera Health had a net margin of 4.10% and a return on equity of 35.74%. The business had revenue of $226.16 million during the quarter, compared to analysts’ expectations of $222.55 million. As a group, equities research analysts predict that Sotera Health will post 0.85 EPS for the current fiscal year.

A number of analysts recently issued reports on the stock. Barclays raised their target price on shares of Sotera Health from $30.00 to $32.00 and gave the stock an overweight rating in a research report on Friday, August 13th. Zacks Investment Research lowered shares of Sotera Health from a hold rating to a sell rating in a research report on Saturday, November 20th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sotera Health has an average rating of Buy and a consensus target price of $32.14.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its stake in shares of Sotera Health by 852.3% in the 2nd quarter. Morgan Stanley now owns 481,151 shares of the company’s stock valued at $11,659,000 after acquiring an additional 430,628 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Sotera Health by 22.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 352,968 shares of the company’s stock valued at $9,230,000 after acquiring an additional 63,674 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Sotera Health by 296.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 41,298 shares of the company’s stock valued at $1,080,000 after acquiring an additional 30,882 shares during the period. Finally, UBS Group AG raised its stake in shares of Sotera Health by 461.7% in the 3rd quarter. UBS Group AG now owns 19,259 shares of the company’s stock valued at $504,000 after acquiring an additional 15,830 shares during the period. Institutional investors own 86.95% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Read More: Cyclical Stocks – What You Should Know

Earnings History and Estimates for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.